Quick Answer
CNBX Pharmaceuticals Inc. reported Operating Income Loss of -$271.7 thousand for the year ending 2025.
- CNBX Pharmaceuticals Inc. showed an increase of +53.4% in Operating Income Loss from 2024 to 2025.
- This data is from CNBX Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on December 1, 2025.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), CNBX Pharmaceuticals Inc.'s Operating Income Loss has declined by 367.5%.
- Historical annual values: Fiscal year 2025: -$271.7 thousand | Fiscal year 2024: -$583.1 thousand | Fiscal year 2023: -$931.4 thousand | Fiscal year 2022: -$2.95 million | Fiscal year 2021: -$2.60 million | Fiscal year 2020: -$3.04 million | Fiscal year 2019: -$3.30 million | Fiscal year 2018: -$3.81 million | Fiscal year 2017: -$1.85 million | Fiscal year 2016: -$280.7 thousand | Fiscal year 2015: -$536.5 thousand | Fiscal year 2014: -$216.1 thousand | Fiscal year 2013: -$58.1 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: